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Effector (Teff) and regulatory (Treg) T cells produce
cytokines that balance immunity and immunopa-
thology at sites of infection. It is not known how
this balance is achieved. Here, we show that Treg
and Teff cells specific for the same foreign peptide:
major histocompatibility complex II (pMHCII) ligand
accumulated preferentially in a subcutaneous site
injected with the relevant antigen plus an adjuvant.
Some of the Treg cells in this site were producing
IL-10 12 days after injection, whereas a similar frac-
tion of the Teff cells were producing IFN-g. Acute
ablation of Treg cells increased the fraction of IFN-
g-producing Teff cells, indicating that Teff function
was limited by the Treg cells. Production of cytokines
by both populations was driven by pMHCII presenta-
tion by local CD11bhi dermal dendritic cells. There-
fore, balanced production of microbicidal and
suppressive cytokines in inflamed skin is achieved
by simultaneous dendritic cell antigen presentation
to Teff and Treg cells.
INTRODUCTION
Cell-mediated immunity is required for the effective elimination
of viruses, intracellular bacteria, parasites, and tumors. This
response is initiated in secondary lymphoid tissue, where naive
CD4+ T cells are stimulated by foreign peptide:major histocom-
patibility complex II (pMHCII) ligands on antigen-presenting cells
(APCs) to proliferate and differentiate into effector cells (Teff
cells). Teff cells express new homing receptors, which facilitate
their migration into the nonlymphoid tissue containing the
antigen (Campbell and Butcher, 2002; Masopust et al., 2001;
Mora et al., 2003; Reinhardt et al., 2001). Once in this location,
Teff cells produce lymphokines, such as IFN-g or IL-4, that acti-
vate other local immunological cells to control or eliminate the
foreign material (Dalton et al., 1993; Gordon, 2003).
The stimulus for cytokine production by Teff cells in nonlym-
phoid tissues is not known. Teff cells may continue to produce
lymphokines in nonlymphoid tissues in a TCR-independent
fashion as a consequence of earlier stimulation in the secondary
lymphoid organs. Alternatively, cytokines present in inflamed
nonlymphoid tissues, such as IL-12 and IL-18, may be sufficientfor inducing Teff production of lymphokines, as has been shown
in vitro (Yang et al., 1999; Yoshimoto et al., 1998). Alternatively,
lymphokine production by Teff cells in the nonlymphoid tissue
may require antigen presentation in that location. Dendritic cells
(DCs) present antigens from certain parasites and viruses to Teff
cells in skin (Lemos et al., 2004; Wakim et al., 2008). Thus, DCs
may be responsible not only for antigen presentation to naive
T cells in secondary lymphoid organs but also to Teff cells in
the nonlymphoid tissue. However, many DCs leave inflamed
nonlymphoid tissue and migrate to the draining lymph node,
suggesting that inflamed tissues may be depleted of DCs.
Thus, it is possible that macrophages and granulocytes, which
can express MHCII and enter sites of inflammation, may be
involved in antigen presentation in these locations (Bryant and
Ploegh, 2004; Shi, 2004; Vincent-Schneider et al., 2001).
Regulatory T cells (Treg cells), defined by expression of the
forkhead box P3 (Foxp3) transcription factor (Fontenot et al.,
2005; Hori et al., 2003), also accumulate in inflamed tissues con-
taining foreign antigen (Suffia et al., 2006). During Leishmania
infection, Treg cells balance the potentially tissue-damaging
effects of microbicidal lymphokines produced by Teff cells, in
this case contributing to the persistence of the pathogen and
concomitant immunity (Belkaid, 2007; Belkaid et al., 2002).
Treg cells produce IL-10 in nonlymphoid tissues, and on the
basis of findings that mice containing IL-10-deficient Treg cells
develop autoimmunity (Annacker et al., 2003; Asseman et al.,
1999; Rubtsov et al., 2008), this seems to be important for their
suppressive function. The origin and specificity of the Treg cells
that accumulate in inflamed nonlymphoid tissues is unclear.
So-called naturally occurring Treg cells have been shown to
arise in the thymus (Tang and Bluestone, 2008), perhaps as
a consequence of self-pMHCII specificity. Alternatively, Treg
cells can differentiate from foreign-pMHCII-specific conven-
tional naive precursors in response to persistent antigen expo-
sure (Knoechel et al., 2005; Kretschmer et al., 2005; Sun et al.,
2007; Thorstenson and Khoruts, 2001). Thus, it is possible that
the Treg cells that accumulate in nonlymphoid sites of infection
are induced Treg cells specific for microbial pMHCII complexes
or naturally occurring Treg cells specific for self-pMHCII
complexes. In either case, it is not clear which type of APC pres-
ents the relevant complexes to Treg cells in nonlymphoid tissues
or even whether such presentation is a requirement for Treg cell
function. In addition, it is not clear that the constant presence of
Treg cells is required in antigen-containing tissues for the damp-
ening of inflammatory-cytokine production by antigen-specific
Teff cells.Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc. 277
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antigen-specific CD4+ T cells and the relevant pMHCII complex
could be tracked under conditions of antigen persistence and
inflammation. Our results show that Teff and Treg cells derived
from the same naı¨ve precursor pool accumulated and produced
cytokines in an inflamed subcutaneous site containing antigen in
response to continuous local antigen presentation by dermal
DCs. Focus on the same APCs may allow Treg cells to efficiently
dampen cytokine production by Teff cells in nonlymphoid
tissues.
RESULTS
CD4+ T Cell Effector Function Requires the Presence
of Antigen in Nonlymphoid Tissue
Subcutaneous injection of incomplete Freund’s adjuvant (IFA)
was chosen for production of a long-term local site of inflamma-
tion that would mimic a chronic infection. Mice were injected in
one ear with a foreign antigen in IFA and with either IFA alone
or an unrelated antigen in IFA in the other ear. This strategy
allowed for the visualization of Teff and Treg cells at an inflamed
site containing the antigen of interest and an inflamed control site
lacking the antigen on the samemouse. In this way, comparisons
about the state of each cell type in the presence or absence of
antigen could be ascertained under conditions of similar inflam-
mation.
An adoptive-transfer system was used for defining the role of
local antigen presentation on CD4+ T cell effector function in
nonlymphoid tissue. The TEa T cell receptor (TCR)-transgenic
mouse specific for the Ea52–68 peptide (pEa) derived from the
MHCII I-Eda chain (Grubin et al., 1997) was used as a source
of T cells. A recombinant protein containing pEa fused to DsRED
(EaRFP) was used as the antigen (Itano et al., 2003). The major
advantage of this approach was that pEa:I-Ab complexes could
be detected and blocked with the pEa:I-Ab-specific Y-Ae mono-
clonal antibody (Murphy et al., 1992; Rudensky et al., 1991) and
antigen uptake could be visualized on the basis of the inherent
fluorescence of the red fluorescent protein (RFP).
Initial experiments involved assessment of the kinetics of total
CD4+ T cell accumulation at the antigen-injection site. One
million CFSE-labeled CD90.1+ RAG-deficient TEa T cells were
injected into CD90.2+ C57BL/6 (B6) mice, which were then
injected intradermally in one ear with EaRFP in IFA and in the
other ear with ovalbumin (OVA) in IFA. TEa CD4+ T cells were
present in an undivided state in the lymph nodes of mice before
antigen injection (left panels of Figures S1A and S1B, available
online) and were completely absent in the ear tissue (data not
shown). Twelve days after antigen injection, the TEa cells in the
lymph nodes draining the EaRFP+IFA-injected ear increased in
number and displayed a heterogeneous pattern of cell division
(Figures S1A and S1B, middle panels). TEa cells also appeared
in the EaRFP+IFA-injection site at this time and showed
evidence of at least six cell divisions (Figures S1A and S1B, right
panels), confirming earlier work finding that the most-divided
T cells migrate to sites of antigen deposition (Reinhardt et al.,
2003; Roman et al., 2002). TEa T cells entered both ears at nearly
the same rate for the first six days but then continued to increase
in the EaRFP+IFA-injection site to a peak on day 12, eventually
leveling off at a 4-fold higher number compared to the278 Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc.OVA+IFA-injection site (Figure 1A). The TEa cells at both sites
then decreased steadily after day 12, eventually falling to very
low numbers by day 25. TEa cells in the EaRFP+IFA-injection
site had elevated amounts of the activation markers CD69 and
CD25 throughout the time course, compared to the TEa cells
in the OVA+IFA-injected ear (Figure 1B).
Lymphokine production was used for assessing the effector
function of CD4+ T cells that accumulated in the subcutaneous
sites. Importantly, lymphokine production was measured
directly ex vivo by intracellular staining in the presence of brefel-
din A for prevention of cytokine release (Khoruts et al., 1998).
This direct approach eliminated the concern that in vitro or
in vivo restimulation with antigen might not accurately reflect
the ongoing in vivo situation. Twelve days after EaRFP+IFA injec-
tion, a fraction of the TEa cells in the injection site were making
IFN-g and/or TNF-a, but very few were making IL-5 or IL-17
(Figure S1C). Subsequent analyses of Teff function were focused
on IFN-g. The 10%–15% of TEa cells that produced IFN–g in
EaRFP+IFA-injection sites on days 6 and 12 was significantly
higher than the 2% of TEa cells that produced IFN-g in
OVA+IFA-injection sites on these same mice at these times
(Figures 1C and 1D). Very few cells in the lymph nodes draining
either the EaRFP- or OVA-injection sites were making IFN-g at 3,
6, or 12 days (Figures 1E and 1F), suggesting that the IFN-
g-producing TEa T cells at the EaRFP-injection sites were not
producing this lymphokine before they reached the injection
site. As shown in Figure 1G, TEa T cells in the OVA+IFA-injected
ear produced IFN-g 3 hr after injection of pEa into that site. Thus,
the TEa T cells that entered the OVA+IFA-injected ear were
capable of IFN-g production if the appropriate antigen was intro-
duced into the tissue. These results reveal that IFN-g production
at the site of antigen deposition in the nonlymphoid tissue occurs
only when antigen-specific CD4+ T cells detect the relevant
pMHCII ligand.
Foxp3+ TEa Cells Produce IL-10 at the Antigen-Injection
Site
TEa Treg cells also accumulated at the sites of EaRFP+IFA injec-
tion. The first hint of this fact came from the observation that the
IFN-g-producing TEa T cells in the EaRFP-containing ears did
not coincide with those expressing CD25 (Figure 2A). Consid-
ering that Treg cells often express CD25 (Sakaguchi et al.,
1995), we stained TEa cells in the ear for the Treg cell-specific
transcription factor Foxp3 (Fontenot et al., 2005; Hori et al.,
2003). Foxp3 was not detected in RAG-deficient TEa T cells prior
to transfer, as reported previously for other TCR-transgenic lines
(Sun et al., 2007) (Figure 2B). Similarly, < 10 Foxp3+ TEa cells
were detected in the lymph nodes of recipient mice after adop-
tive transfer but before EaRFP injection (Figure 2C). However,
a large population of Foxp3+ TEa T cells was present in lymph
nodes draining the EaRFP-injection site by day 12 (Figure 2C).
A time-course experiment revealed that although the number
of Foxp3 TEa cells peaked at day 6 after EaRFP+IFA injection,
Foxp3+ TEa cells were still increasing on day 12, accounting for
approximately 20%of the total TEa population in the lymph node
(Figure 2C). The percentage of Foxp3+ TEa T cells in the EaRFP-
containing ear at this timewas even greater than that observed in
the lymph nodes (Figure 2D). These results demonstrate that
Treg cells were induced from Foxp3 naive TEa cell precursors
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Figure 1. Antigen-Specific CD4+ T Cell
Accumulation and Activation at Sites of
Antigen Injection
B6 recipients of TEa T cells were injected with
EaRFP+IFA in one ear and OVA+IFA in the other.
(A) Mean number ± SD (n = 2/time point) of TEa
T cells in the EaRFP+IFA-injection (closed
squares) or OVA+IFA-injection (open squares)
sites over time.
(B) Mean percentage ± SD (n = 2/time point) of
CD69+ (top graph) or CD25+ (bottom graph) TEa
T cells in the indicated injection sites from mice
in (A).
(C) Intracellular IFN-g in TEa cells in the indicated
sites 12 days after antigen injection.
(D) Percentages (n = 2–6, pooled from three exper-
iments) of IFN-g+ TEa cells obtained from the gates
shown in (C) in the EaRFP+IFA-injection (filled
squares) or OVA+IFA-injection (open squares)
sites 6 or 12 days after injection.
(E) Intracellular IFN-g in TEa cells in the cervical
lymph node at 6 (left panel) or 12 (right panel)
days after antigen injection.
(F) Percentages of IFN-g+ TEa cells obtained from
the gates shown in (C) or (E) in the EaRFP+IFA-
injection sites or draining cervical lymph nodes 3,
6, or 12 days after injection. Statistical differences
shown are for ears versus all lymph nodes.
(G) Intracellular IFN-g in TEa cells in initial
OVA+IFA-injection sites 3 hr after challenge in
those sites with PBS (left panel) or 40 mg of pEa
(right panel). Data in (G) are representative of
results obtained in three independent experi-
ments. IFN-g+ gates were determined by staining
comparable samples with an isotype control anti-
body, as was the case for intracellular-cytokine-
staining experiments shown in other figures. Single
asterisk indicates p % 0.05, double asterisk indi-
cates p% 0.01, triple asterisk indicates p% 0.001.in the lymph nodes late in the primary response. In addition, TEa
Treg cells accumulated preferentially at the EaRFP-injection site
in the same manner as Teff cells with the same specificity
(Figure 2E).
We next determined whether the induced TEa Treg cells in the
EaRFP-injection siteswereactivatedasevidencedbyproduction
of IL-10, an important suppressive cytokine (Belkaid, 2007; Tang
and Bluestone, 2008). TEa T cells from ears and draining lymph
nodes were stained for Foxp3, IL-10, and IFN-g directly ex vivo.
As before, the cells were not restimulated in vitro, for determina-
tion of the true in vivo state of cytokine production. About 15%of
the Foxp3+ TEa T cells in EaRFP-containing ears were making
IL-10, compared to only 5% of the Foxp3+ TEa cells in the lymph
nodes (Figures 2F and 2G). The majority of IL-10-producing TEa
cells in the injection site were Foxp3+, whereas the majority of
IFN-g-producing TEa cells were Foxp3 (Figure 2H).
Together, the results demonstrate that Foxp3+ cells capable of
producing IL-10 in a nonlymphoid tissue containing the relevant
antigen can be induced from a naive population of T cells and
can coexist in the same tissue with Teff cells of the same origin.Nonlymphoid Activation of Endogenous
Antigen-Specific CD4+ T Cells
The preceding results depended on the adoptive transfer of large
numbers of antigen-specific T cells from TCR-transgenic mice.
A limitation of this approach is that T cells may receive less
intense antigenic stimulation when present in large numbers,
perhaps because of intraclonal competition (Badovinac et al.,
2007; Blair and Lefrancois, 2007; Foulds and Shen, 2006; Hataye
et al., 2006; Marzo et al., 2005).
To validate the use of the adoptive-transfer system in this
model, we investigated the activation state of an endogenous
antigen-specific CD4+ T cell population. B6 mice were injected
intradermally in one ear with the immunogenic peptide 2W1S
(Rees et al., 1999) emulsified in IFA or in the other ear with emul-
sified IFA alone. Negative control mice received IFA alone in both
ears. Twelve days after injection, ears and draining lymph nodes
were harvested and single-cell suspensions were prepared from
each tissue. 2W1S:I-Ab tetramers (Moon et al., 2007; Rees et al.,
1999) were used for detecting antigen-specific CD4+ T cells
by flow cytometry. 2W1S:I-Ab-specific CD4+ T cells were notImmunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc. 279
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Figure 2. Antigen-Specific Treg Cells
Produce IL-10 in Antigen-Injection Sites
(A) Representative (six independent experiments)
intracellular IFN-g versus CD25 staining in TEa
cells in an EaRFP+IFA-injection site from a B6
recipient of TEa cells injected with EaRFP+IFA
12 days earlier.
(B) Isotype control (left panel) or intracellular
Foxp3+ (right panel) staining of CD4+ T cells from
a TEa TCR-transgenic RAG1-deficient mouse.
(C) Mean number ± SD (n = 2/time point) of Foxp3
(closed squares) or Foxp3+ (open squares) TEa
T cells in the draining lymph nodes of mice injected
with EaRFP+IFA. The number of Foxp3 TEa cells
was calculated by subtracting the number of
Foxp3+ TEa cells from the total number of TEa
cells.
(D) Intracellular Foxp3 staining of TEa cells from
draining lymph nodes (left panel) or antigen-injec-
tion sites (right panel) 12 days after EaRFP+IFA
injection.
(E) Number of Foxp3+ TEa cells in the indicated
injection site from individual TEa recipient mice
(from two experiments) 12 days after injection of
EaRFP+IFA in one ear and OVA+IFA in the other.
Asterisk indicates p = 0.04.
(F) Intracellular IL-10 in the Foxp3+ TEa population
from the draining lymph node (left panel) or
antigen-injection site (right panel) 12 days after
EaRFP+IFA injection.
(G) Percentages of IL-10+Foxp3+ TEa cells from
antigen-injection sites (closed squares) or draining
lymph nodes (open squares) 12 days after injection
of EaRFP+IFA (n = 9, from three pooled experi-
ments). Asterisk indicates p = 0.007.
(H) Intracellular IFN-g (left panel) or IL-10 (right
panel) versus Foxp3 in TEa cells from EaRFP+
IFA-injection sites 12 days after injection.
Percentage of total cells is shown in each quad-
rant.detected in the ears ofmice injectedwith IFA alone (Figure 3A). In
contrast, 2W1S:I-Ab-specific CD4+ T cells were present in
2W1S-containing ears and were much more numerous in this
site than in the IFA-only-containing ear on the same mouse
(Figure 3B).
Several additional pieces of evidence indicated that the
2W1S:I-Ab-specific CD4+ T cells behaved like the TEa cells after
antigen+IFA injection. A much larger fraction of the 2W1S:I-Ab-
specific CD4+ T cells in 2W1S+IFA-injection sites expressed
CD69 and/or CD25 than the comparable cells in IFA-injected
ears (Figure 3C). In addition, 10% of the 2W1S:I-Ab-specific
CD4+ T cells in 2W1S-containing ears were producing IFN-g,
compared to less than 2% in IFA-injected ears (Figure 3D).
Thus, like the TEa T cells, endogenous antigen-specific CD4+
T cells accumulated and showed signs of activation only in
antigen-containing subcutaneous tissues. Similarly, using
Foxp3-green fluorescent protein (GFP) reporter mice, we found
that 2W1S:I-Ab-specific CD4+ T cells from antigen-containing
ears consisted of at least two subsets: a Foxp3 population,
more of which produced IFN-g than IL-10, and a Foxp3+ popu-
lation that produced IL-10 but not IFN-g (Figures 3E and 3F).
Additionally, like TEa T cells, 2W1S:I-Ab-specific CD4+ Treg cells
arose later in the primary response than the Teff population (data280 Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc.not shown) (Korn et al., 2007). The similarity between the
endogenous and TCR-transgenic T cells validated the use of
the adoptive-transfer approach for subsequent study of Treg
and Teff cells in this model system.
Continuous Antigen Presentation Is Required for Both
Teff and Treg CD4+ T Cell Cytokine Production
in the Skin
The differences in T cell activation between sites that contained
antigen and those that did not raised the possibility that APCs
displaying antigen-derived pMHCII complexes were activating
antigen-specific T cells in the former locations. We tested this
possibility by assessing the capacity of the pEa:I-Ab-specific
Y-Ae antibody to block the activation of TEa cells in EaRFP-
injection sites. B6 recipients of TEa cells were injected in both
ears with EaRFP+IFA. At various times thereafter, Y-Ae or
isotype control antibody was injected directly into the antigen-
containing sites of separate groups of mice. IL-10 and IFN-g
production by TEa cells in the Foxp3+ and Foxp3 populations,
respectively, was measured directly ex vivo 4 hr after antibody
injection. This short time frame was chosen so that the potential
contribution of TEa T cells migrating to the ear from draining
lymph nodes was minimized and yet the suppression of cytokine
Immunity
Dermal DCs Drive Skin T Cell Cytokine Productionproduction was allowed for, as has been described for CD8+
T cells in vitro (Slifka et al., 1999).
Remarkably, the percentage of both IL-10- and IFN-
g-producing Foxp3+ and Foxp3 TEa cells in EaRFP-injection
sites was significantly reduced 4 hr after Y-Ae administration
(Figures 4A and 4B). The endogenous CD4+ T cell populations
in the ear, which were presumably specific for other peptides
derived from EaRFP, were unaffected (Figures 4C and 4D),
demonstrating the specificity of the Y-Ae blockade.
Although these results indicated that the cytokine-producing
T cells were being stimulated by local pMHCII recognition, it
was still possible that this stimulation occurred in the lymph
nodes and was maintained by the T cells after migration into
the ear tissue. This possibility was addressed through prevention
of T cell egress from lymph nodes with an S1P1 receptor agonist
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Figure 3. Endogenous Antigen-Specific Teff and Treg CD4+ T Cells
Are Activated in Antigen-Injection Sites
(A) 2W1S:I-Ab versus CD44 staining for CD4+ T cells in the injection sites of B6
mice injected in both ears with PBS+IFA 12 days earlier.
(B) 2W1S:I-Ab versus CD44 staining for CD4+ T cells in the indicated injection
sites of B6 mice injected 12 days earlier with PBS+IFA (left panel) in one ear
and 2W1S+IFA (right panel) in the other.
(C) CD25 versus CD69 expression or (D) intracellular IFN-g production by
2W1S:I-Ab-specific cells in the PBS+IFA- (left panel) or 2W1S+IFA- (right
panel) injection sites of mice shown in (B).
Data in (B–D) are representative of three independent experiments.
(E) IFN-g or (F) IL-10 versus Foxp3 staining for 2W1S:I-Ab-specific CD4+ T cells
in 2W1S+IFA-injection sites 12 days after injection. The percentages of total
cells are shown in each quadrant. Similar results were obtained in two inde-
pendent experiments.(Matloubian et al., 2004). Mice that received TEa cells were
injected with EaGFP in the ears, then at the plateau of T cell infil-
tration into the ear, with an S1P1 receptor agonist or the relevant
vehicle only. After 24 hr, the number of TEa cells in the blood of
mice injected with the S1P1 agonist was much lower than the
number in vehicle-injected mice, indicating that lymph-node
egress was blocked (Figure S2A). However, IFN-g production
by TEa cells in the ear injection sites was identical in both groups
at this time (Figure S2B), ruling out the possibility that these
T cells were recent migrants from the lymph nodes. This finding,
together with the Y-Ae blocking results, suggested that antigen
presentation in the antigen-injection sites was driving the
production of both suppressor and inflammatory cytokines by
antigen-specific Teff and Treg cells in this location.
Dendritic Cells Present Antigen in the Skin
We next sought to identify the APCs that were stimulating
lymphokine production by Teff and Treg cells in the skin.
Nonhematopoetic cells (CD45), hematopoetic non-DCs
(CD45+CD11c), and DCs (CD45+CD11c+) were FACS sorted
from ears injected 12 days earlier with either EaRFP+IFA or
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Figure 4. Cytokine Production by Antigen-Specific Treg and Teff
CD4+ T Cells in Antigen-Injection Sites Is Dependent on pMHCII
Recognition
IFN-g (A and C) or IL-10 (B andD) production by Foxp3 TEa T cells (A), Foxp3+
TEa T cells (B), endogenous Foxp3CD4+ T cells (C), or endogenous Foxp3+
CD4+ T cells (D) 4 hr after injection of Y-Ae antibody or an isotype control anti-
body into day 12 EaRFP+IFA-injection sites. Data in scatterplots correspond
to 7–8 individual mice from two experiments. ‘‘n.s.’’ denotes not significant;
single asterisk indicates p = 0.0007, double asterisk indicates p = 0.004.Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc. 281
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Figure 5. DCs Are the Only Cells in Antigen-Injection Sites that
Present Antigen and Induce T Cell Lymphokine Production
(A) Representative CD11c versus CD45 staining for cells isolated from the ears
of B6 mice injected 12 days earlier with either EaRFP+IFA or OVA+IFA.
(B) CFSE dilution of naive TEa T cells incubated with cells sorted on the basis of
the gates shown in (A). The sorted populations were from OVA+IFA-injection
sites (top rows) or EaRFP-injection sites (bottom rows). Gates indicate the
percentage of TEa cells that proliferated during the culture. Data are represen-
tative of three individual experiments.
(C) Representative GFP versus CD11c staining of anti-CD11c magnetic-bead-
enriched cells from antigen-injection sites of CD11c-DTRmice 24 hr after PBS
(left panels) or DT injection (right panels). Scatterplots on the right show the
percentage of DCs in samples from individual mice.
(D and E) Representative intracellular IFN-g staining of Foxp3 (D) or IL-10 (E)
staining of Foxp3+ TEa T cells from CD11c-DTR recipients injected with
EaRFP+IFA, then 11 days later with DT (right panels) or PBS (left panels) into
the original injection sites. Intracellular staining was performed 24 hr after
DT or PBS injection. Scatterplots (far right panels) show the percentage
of cytokine-producing TEa T cells from individual mice (n = 7, from two pooled
experiments). Asterisk indicates p < 0.0001, double asterisk indicates p =
0.0005, triple asterisk indicates p = 0.02.282 Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc.OVA+IFA (Figure 5A). The sorted cells were cultured at a 1:1 ratio
with naive TEa-transgenic T cells in the presence of IL-2. As
shown in Figure 5B, the only cell type capable of stimulating
the proliferation of TEa cells were DCs obtained from the
EaRFP-injected ear.
The sorting results were confirmed by acute depletion of DCs
from injection sites. TEa T cells were transferred into CD11c-
DTR-transgenic mice (Jung et al., 2002), which express GFP
and the diptheria toxin (DT) receptor (DTR) under the control of
the CD11c promoter. Mice were then injected in both ears with
EaRFP+IFA. Eleven days after injection, one group of mice was
injected with DT for elimination of DCs. A separate PBS-injected
group was used as a positive control for cytokine production.
Twenty-four hours after DT injection, EaRFP+IFA-injected ears
were harvested and single-cell preparations were analyzed by
flow cytometry. As expected, the percentage of CD11c+GFP+
cells in the ear dropped by 70% (Figure 5C) in CD11c-DTR-trans-
genic mice injected with DT. In addition, both IL-10 production at
the injection site in the Foxp3+ and IFN-g production in the
Foxp3 TEa populations dropped significantly (p = 0.02 and
p = 0.0005, respectively) in DC-ablated mice, compared with
the DC-sufficient controls (Figures 5D and 5E). The incomplete
abrogation of cytokine production by TEa T cells was consistent
with the partial depletion of DCs. Together, these data provided
evidence for a DC population at antigen+IFA-injection sites that
is essential for both the suppressor and the effector functions of
antigen-specific CD4+ T cells in this location.
Dermal Dendritic Cells Present Antigen in the Skin
It was of interest to identify the type of CD11c+ DC that was
responsible for antigen presentation in the intradermal injection
sites. Our analyses focused on Langerin dermal DCs, epidermal
Langerhans cells, newly discovered dermal Langerin+ cells, and
plasmacytoid DCs, all of which can be found in inflamed skin
(Bursch et al., 2007; Ginhoux et al., 2007; Kissenpfennig et al.,
2005; Poulin et al., 2007; Valladeau and Saeland, 2005). As
shown in Figure 6A, the number of CD11c+ cells in the injection
sites increased dramatically between day 1 and day 12 when
cytokine-producing Teff and Treg cells were present. On day
12, > 90% of the CD11c+ cells in the injection sites expressed
high amounts of CD11b and low amounts of F4/80 (Figure 6B).
Langerin-GFP reporter mice (Kissenpfennig et al., 2005) were
used for assessing the presence of epidermal Langerhans cells
or dermal Langerin+ cells. Langerin+ cells were clearly identified
in the CD11c+ population in the ear injection sites of these mice
on the basis of comparison with cells from normal B6 mice
(Figure 6C). However, the Langerin+ cells accounted for only
1%–3% of the total CD11c+ cells in the ear injection sites and
were distinguished from the large CD11bhi population by lower
expression of CD11b. The expression of F4/80 but not Langerin
identified the abundant CD11bhi population as dermal DCs
(Bogunovic et al., 2006). The small Langerin+ population con-
tained epidermal Langerhans cells and dermal Langerin+ cells.
Plasmacytoid DCs, identified by expression of B220 on the basis
of a gate from the clearly resolved comparable population in
lymph nodes, accounted for less than 1% of the CD11c+ popu-
lation in the injection sites (Figure 6D). Finally, about the 5% of
the cells in the CD11c+ population did not express CD11b,
B220, or Langerin. These cells may have been CD8+ effector
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Figure 6. Dendritic Cells Present Antigen in
Injection Sites throughout the Primary
Immunological Response
Single-cell preparations from the ears of B6 mice
injected with either EaRFP+IFA in both ears or
OVA+IFA in both ears were enriched as indicated.
The events shown in (A) and (B) represent viable
cells, those shown in (C), (D), (F), (G), and (H) repre-
sent CD11c+ cells, and those shown in (E) repre-
sent CD11c+CD11bhi cells.
(A) CD11c staining versus forward light scatter of
anti-MHCII magnetic-bead-enriched cells from
EaRFP+IFA-injection sites of B6 mice 24 hr or
12 days after injection. Numbers indicate the
percentage of cells in the CD11c+ gate.
(B) CD11c versus CD11b staining (left panel) of
anti-CD11c magnetic-bead-enriched cells from
EaRFP+IFA-injection sites of B6mice 12 days after
injection. F4/80 staining (right panel, thick line) is
shown for the CD11c+CD11bhi cells from the left
panel. The shaded histogram shows staining of
the same population with an isotype control anti-
body.
(C) CD11b staining versus Langerin expression in
anti-CD11c magnetic-bead-enriched cells from
EaRFP+IFA-injection sites of control B6 mice (left
panel) or Langerin-GFP-transgenic mice (right
panel) 12 days after injection. Dermal Langerin+
cells were identified in the left gate and epidermal
Langerhans cells in the right gate in the panel from
Langerin-GFP-transgenic mice. Numbers indicate
the percentage of cells in the indicated gates.
(D) B220 versus CD11b staining for anti-CD11c
magnetic-bead-enriched cells from lymph nodes
(left panel) or EaRFP+IFA-injection sites (right
panel) of B6 mice 12 days after injection. Plasma-
cytoid DCs were identified as B220+CD11b cells
on the basis of the gate from the lymph nodes (left
panel). A population of B220CD11b cells was
also identified with this staining combination.
(E) Y-Ae staining (left panel) and antigen uptake
(right panel) in the CD11c+CD11bhi cells (dermal DCs) in (B) in Y-Ae magnetic-bead-enriched populations from OVA+IFA- (shaded) or EaRFP+IFA- (thick line)
injection sites of B6 mice 12 days after injection.
(F andG) Y-Ae staining (left panel) and antigen uptake (right panel) in the Langerin+CD11b cells (dermal Langerin+ DCs) (F) and Langerin+CD11b+ cells (epidermal
Langerhans cells) cells (G) in (C) in anti-CD11c magnetic-bead-enriched populations from OVA+IFA- (shaded) or EaRFP+IFA- (thick line) injection sites of
Langerin-eGFP mice 12 days after injection.
(H) Y-Ae staining in the B220+CD11b (plasmacytoid DCs) and B220CD11b cells in (D) in anti-CD11c magnetic-bead-enriched populations from OVA+IFA-
(shaded) or EaRFP+IFA- (thick line) injection sites of B6 mice 12 days after injection. Data are representative of 2–5 independent experiments.T cells, which can express CD11c (Huleatt and Lefrancois, 1995).
Together, these results showed that the vast majority of the
CD11c+ cells in the ear injection sites were CD11bhi dermal
DCs, along with trace populations of epidermal Langerhans
cells, dermal Langerin+ cells, and plasmacytoid DCs.
The Y-Ae antibody was then used for detection of pEa:I-Ab-
complex production by these DC subsets. As shown in the left
panel of Figure 6E, the display of pEa:I-Ab complexes on the
abundant CD11bhi dermal DC population in EaRFP+IFA-injec-
tion sites on day 12 was 2.4 ± 0.35 (mean ± SD, n = 4) times
higher than that of the comparable population in OVA+IFA-injec-
tion sites. pEa:I-Ab complexes were also detected on the rare
epidermal Langerhans cells and dermal Langerin+ cells, but not
on the plasmacytoid DCs or CD11bCD11c+ cells in EaRFP+
IFA-injection sites (Figures 6F and 6G, left panels; Figure 6H).
Notably, the CD11bhi dermal DC population took up far moreantigen in the site at day 12, compared to the Langerin+ dermal
DCs or the Langerhans cells (Figures 6E–6G, right panels).
Although the CD11bhi dermal DCs from the previous experi-
ment were 100 times more prevalent than any other DC in the
inflamed skin, it was still possible that the Langerin+ DCs were
responsible for stimulation of the T cells. Langerin-DTR mice,
which express the DTR and GFP under control of the Langerin
promoter, were used for testing of this possibility. These mice
received DT 11 days after injection of 2W1S in IFA. Ears were
harvested on day 12, and Langerin+ DC ablation was confirmed
by staining for CD11c and GFP (Figures S3A and S3B). Although
nearly all of the Langerin+ DCs were ablated, IFN-g in the
2W1S:I-Ab-specific Foxp3CD4+ T cells and IL-10 in the
Foxp3+CD4+ T cells was unaffected (Figures S3C and S3D).
These results demonstrate that the Langerin+ DCs in the skin
do not contribute appreciably to stimulation of cytokineImmunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc. 283
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This function was therefore likely to be carried out by CD11bhi
dermal DCs, which were the only other APC in this site that
displayed detectable pMHCII complexes.
Treg Cells Actively Suppress Teff Cell IFN-g Production
in the Skin
The simultaneous activation of antigen-specific Teff and Treg
cells by CD11bhi dermal DCs in the antigen-injection sites raised
the possibility that the Treg cells were suppressing the activity of
the Teff cells. This possibility was addressed by measuring the
effect of acute depletion of the Treg cells on lymphokine produc-
tion by the Teff cells. This was accomplished through the use of
Foxp3-DTR mice, which express the DTR in Treg cells under the
control of the Foxp3 promoter (Kim et al., 2007). Foxp3-DTR
mice were injected with 2W1S peptide+IFA in both ears, and
10 and 11 days later, one group of mice was injected with DT
while a control group was injected with PBS. Twenty-four hours
after the last DT injection, ears were harvested and IFN-g was
assessed directly ex vivo in the Foxp3 2W1S:I-Ab-specific
CD4+ T cells. As shown in Figure 7A, Treg cells were completely
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Figure 7. Ablation of Treg Cells Increases IFN-g Production by
Antigen-Specific Teff Cells in Antigen-Injection Sites
(A and B) Foxp3-DTR mice were injected in the ear with 2W1S+IFA, then 11
days later with PBS (left panels) or DT (right panels). (A) Representative
Foxp3-GFP versus CD25 staining of total CD4+ T cells from 2W1S+IFA-injec-
tion sites of Foxp3-DTR mice 24 hr after injection of PBS (left panels) or DT
(right panels). (B) Representative intracellular IFN-g staining of Foxp3,
2W1S:I-Ab-specific CD4+ T cells in 2W1S+IFA-injection sites 24 hr after injec-
tion of PBS (left panels) or DT (right panels).
(C) Scatterplot shows the percentage of IFN-g-producing Foxp3, 2W1S:I-Ab-
specific CD4+ T cells in 2W1S+IFA-injection sites 24 hr after PBS (closed
squares) or DT injection (open squares; from three pooled experiments).
Asterisk indicates p = 0.0002.284 Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc.eliminated from the ear tissues of the DT-treated mice. Under
these conditions, 35% of the Foxp3 2W1S:I-Ab-specific CD4+
Teff cells produced IFN-g, compared to 15% of the cells in
PBS-injected control mice (Figures 7B and 7C). This result
demonstrated that Treg cells constantly limit the production of
IFN-g by Teff cells specific for the same pMHCII ligand in
a subcutaneous site of antigen deposition.
DISCUSSION
Our results with monoclonal TEa cells demonstrate that the Teff
and Treg cells that accumulate in a nonlymphoid tissue can be
derived from the same Foxp3 naive antigen-specific popula-
tion. This finding adds to the growing body of evidence indicating
that Teff and Treg cells are alternate progeny of naive cells from
the foreign antigen-specific repertoire (Knoechel et al., 2005;
Kretschmer et al., 2005; Sun et al., 2007). Our studies rule out
TCR affinity as the only determinant of Teff or Treg cell fate, given
that monoclonal naive TEa cells could adopt either fate. It is also
possible that the polyclonal 2W1S:I-Ab-specific Treg cells were
generated from Foxp3 naive precursors, because natural
Treg cells are underrepresented in the naive 2W1S:I-Ab-specific
population (Burchill et al., 2008).
Our results provide definitive evidence for the suggestion of
Belkaid and colleagues (Suffia et al., 2006) that cytokine produc-
tion by some of the Teff and Treg cells in nonlymphoid tissues is
driven by local DCs displaying pMHCII complexes derived from
the foreign antigen. The alternative possibility that Teff or Treg
cells began producing IFN-g or IL-10 in the lymph nodes and
then simply continued that production in a TCR-independent
fashion after migrating to the injection site was ruled out on the
basis of several pieces of evidence. First, very few antigen-
specific IFN-g-producing cells were found in the draining lymph
nodes at any time after injection of antigen. Second, a higher
fraction of antigen-specific IFN-g-producing cells was found in
the injection site containing the relevant antigen than in a site
on the same mouse containing an irrelevant antigen. This finding
is difficult to reconcile with a TCR-independent process. Third,
lymphokine production by Teff or Treg cells in the injection sites
was not affected by blockade of T cell egress from the secondary
lymphoid organs. Fourth, blockade of the relevant pMHCII ligand
rapidly terminated lymphokine production, proving that nonspe-
cific inflammatory signals, such as cytokines—for example,
IL-12 and IL-18 (Yang et al., 1999; Yoshimoto et al., 1998)—did
not sustain lymphokine production in the absence of continued
TCR stimulation.
CD11bhi dermal DCs were probably the key APC in subcuta-
neous injection sites because they were the most numerous of
the three DC subsets that produced pMHCII complexes from
the injected antigen. The dominance of CD11bhi dermal DCs
over dermal langerin+ cells and epidermal Langerhans cells
could not be explained by the production of more pMHCII
complexes. Although CD11bhi dermal DCs took up the most
antigen, they actually produced fewer pMHCII complexes than
the other two cell types. Thus, despite being relatively inefficient
with respect to antigen processing, CD11bhi dermal DCs
became important APCs because their high frequency at the
injection site increased the likelihood of contacting a Teff or
Treg cell.
Immunity
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tion sites over time indicates a rapid recruitment from the blood,
perhaps as monocytes (Geissmann et al., 2003; Ginhoux et al.,
2006). DCs with a similar phenotype have been implicated in
antigen presentation in other nonlymphoid tissues. For example,
CD11b+ DCs in the lungs of mice that inhale the Leishmania
LACK antigen present LACK-derived pMHCII complexes as
late as 8 wk after antigen exposure (Julia et al., 2002). This
ongoing presentationmaymaintain CD4+ T cell IFN-g production
in the airways, which is an important component of allergic
asthma (Kumar et al., 2004).
The simultaneous presence of Teff and Treg cells activated by
the same pMHCII ligand on DCs at the injection site may be
a mechanism that balances the antimicrobicidal but potentially
toxic effect of IFN-g. Although IFN-g is required for elimination
of certain pathogens (Dalton et al., 1993), it has also been impli-
cated in the induction of several serious autoimmune disorders,
including diabetes (Wang et al., 1997) and systemic lupus eryth-
ematosus (Seery et al., 1997). Conversely, a lack of IL-10 in
T cells can lead to amplified colitis, increased skin hypersensi-
tivity, and lethality in mice infected with Toxoplasma gondii
(Roers et al., 2004).
The reliance on DC antigen presentation suggests a mecha-
nism whereby a balance between IL-10 and IFN-g production
may be struck. One possibility is that the counterbalancing
effects of each population on the other are optimized by coloc-
alization on the same DCs. In this way, the cytokines produced
by one population would be focused in the area occupied by
the other. Our finding that eliminating Treg cells tips the balance
of cytokine production by pMHCII-specific T cells in favor of
IFN-g supports this possibility. It is feasible that the IL-10
produced by Treg cells limits IFN-g production by Teff cells.
This contention is supported by the findings that IL-10 produc-
tion by Treg cells limits the delayed-type hypersensivity reaction
(Rubtsov et al., 2008), which is mediated in part by IFN-g (Timo-
shanko et al., 2002). This suppression could occur via an indirect
effect on the DCs. IL-10 can inhibit CD80, CD86, and MHCII
expression by DCs, thereby reducing the ability of these cells
to stimulate T cells (Mahnke et al., 2007). It is reasonable to
expect that the DCsmost susceptible to this type of suppression
would be those that actually present pMHCII to Treg cells and
stimulate their IL-10 production. It is also possible that Treg cells
act via an IL-10-independent mechansism—for example,
competition with Teff cells for pMHCII ligands on the same
DCs in the nonlymphoid tissues. This competition may create
a state of mutual deterrence, in which neither population can
be stimulated too strongly. Along these lines, it is notable that
in the case of both the transgenic TEa cells and the endogenous
T cells, the number of Treg cells in the injection site was about the
same as the number of Teff cells. Thus, it is possible that under
conditions of chronic infection, neither cell type would be able to
out-compete the other, in effect maintaining the cytokine
balance in the tissue.
EXPERIMENTAL PROCEDURES
Mice
Six- to eight-week-oldmale B6micewere purchased from the National Cancer
Institute mouse repository (Frederick, MD). TEa TCR-transgenic RAG1-defi-cient mice expressing the CD90.1 allele (Grubin et al., 1997) and CD11c-
DTR mice (Jung et al., 2002) were bred onsite. Foxp3-GFP mice (Fontenot
et al., 2005) were a gift of S. Way at the University of Minnesota. Foxp3-DTR
(Kim et al., 2007) mice were obtained from A. Rudensky at the University of
Washington. Langerin-eGFP (Kissenpfennig et al., 2005) and heterozygous
Langerin-DTR (used as described in Bursch et al., 2007) mice were a generous
gift of K. Hogquist at the University of Minnesota. Mice were housed in
a specific pathogen-free facility at the University of Minnesota, and experi-
ments were conducted according to federal and institutional guidelines, with
the requisite approval of the University of Minnesota Institutional Animal
Care and Use Committee.
Antigens and Injections
The EaRFP was prepared as previously described (Itano et al., 2003). Whole
chicken OVA was purchased from Sigma-Aldrich. 2W1S peptide (AWGALAN
WAVDS) was purchased from Invitrogen. For blocking experiments, Y-Ae anti-
body produced from the Y-Ae hybridoma (a generous gift from A. Rudensky)
(Murphy et al., 1992; Rudensky et al., 1991) was injected directly into the
ears of immunized mice at a concentration of 20 mg per ear 4 hr before mice
were sacrificed for analysis. IgG2b isotype control antibody (Sigma, St. Louis,
MO) was injected into separate mice as a negative control. DT (Sigma, St.
Louis, MO) was administered to mice by i.p. injection at 1 mg (for Langerin-
DTR), 4 ng/g body weight (for CD11c-DTR), or 50 mg/kg body weight (for
Foxp3-DTR). S1P1 receptor agonist (Merck) was injected i.p. at 20 mg/mouse.
DT- and S1P1-agonist injectionswere administered 24 hr before tissue harvest
(for Langerin-DTR and CD11c-DTR) or at both 24 and 48 hr before harvest (for
Foxp3-DTR).
Adoptive Transfer and Antigen Injection
Pooled spleen and lymph-node cells from naive CD90.1+ TEa TCR-transgenic
RAG1-deficient donor mice were used for adoptive transfer. One million TEa
cells were transferred i.v. into each CD90.2+ B6 recipient. Twenty-five micro-
grams of antigen in 10 ml of 1:1 IFA emulsion was injected intradermally into the
ear. A 1:1 PBS+IFA emulsion was used as a negative control.
Tissue Harvest and Cell Preparation
Antigen-injected ears and draining cervical lymph nodes were removed and
placed immediately into ice-cold buffer (RPMI1640, 2% FCS, 10 mM HEPES).
Ears were then pulled apart to expose the underlying dermis. The dermal layer
was scraped and the ear was minced. Collagenase D (Roche Diagnostics,
Penzberg, Germany) was added to each tissue at a final concentration of
300 Mandl U/ml. Lymph nodes were incubated at 37C/5% CO2 for 40–60
min, mashed with the back of a 3 ml syringe, and passed through a 100 mm
nylon screen (Sefar Filtration, Depew, NY). Ears were incubated for 30 min in
37C/5% CO2, mashed with the back of a 3 ml syringe, incubated for an addi-
tional 20–30 min, then filtered as described above. The remaining tissue on the
screen was remashed, rinsed with PBS (+ 5 mM EDTA, 2% FCS), and filtered
again. The resulting single-cell suspensions were washed with PBS (+ 5mM
EDTA, 2% FCS) and centrifuged. The supernatant was aspirated, and the
pellet was resuspended in culture supernatant containing 24G2 antibody
(ATCC) plus 1% mouse serum (Sigma) and 1% rat serum (Sigma) (FcBlock)
for blocking of Fc receptors. Samples were then stained for surface markers
as described below. DCs were identified in the CD11c-DTR DC-ablated ears
after anti-CD11c magnetic-bead enrichment (Miltenyi). DCs were identified
as CD11c+GFP+ cells by flow cytometry.
Detection of Adoptively Transferred TEa T Cells and Endogenous
2W1S-Specific T Cells
Single-cell preparations from recipients of TEa cells were incubated briefly in
FcBlock and then stained with PerCP-labeled anti-CD90.1, PE-Cy7-labeled
anti-CD4, FITC-labeled anti-CD69, allophycocyanin-labeled anti-CD25, and
a non-T cell cocktail containing Pacific Blue-labeled anti-B220, anti-CD8,
anti-F4/80, anti-CD11b, and anti-CD11c. TEa T cells were identified as non-
T cell cocktail, CD4+, andCD90.1+ cells. In Figure 2B and Figure S2C, TEa cells
are shown enriched with magnetic beads as previously described (Hataye
et al., 2006). Endogenous antigen-specific T cells were identified with
2W1S:I-Ab/SA-PE or SA-allophycocyanin tetramers (Moon et al., 2007; Rees
et al., 1999). Single-cell preparations from each tissue were incubated forImmunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc. 285
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the SA-allophycocyanin tetramer) tetramer in 1:1 FcBlock and sorter buffer
(PBS +2% FCS +0.1% sodium azide). Cells were then washed in sorter buffer
and stained with FITC-labeled anti-CD3, PerCP-Cy5.5-labeled anti-CD4,
PE-Cy7-labeled anti-CD69, APC-labeled anti-CD25, Alexa Fluor 700-labeled
anti-CD44, Pacific Orange-labeled anti-CD8, and a Pacific Blue-labeled
non-T cell cocktail-containing anti-F4/80, anti-B220, anti-CD11c, and anti-
CD11b. 2W1S-specific T cells were identified as CD3+, non-T cell cocktail,
CD4+, CD8, tetramer+, CD44+ events.
Direct Ex Vivo IL-10 and IFN-g Staining
Single-cell preparations from ears and draining lymph nodes were prepared as
already described, with the following exceptions. Ten micrograms per milliliter
of brefeldin A was present throughout the collagenase digestion, for preven-
tion of cytokine exocytosis. Surface staining for TEa T cells was performed
on ice with FITC-labeled anti-CD90.1, PE-Cy7-labeled anti-CD4, and a non-
T cell cocktail containing Pacific Blue-labeled anti-B220, anti-CD8, anti-F4/
80, anti-CD11b, and anti-CD11c. Surface staining for endogenous antigen-
specific T cells was performed with 2W1S:I-Ab/SA-allophycocyanin tetramers
as described earlier in the presence of brefeldin A. Cells were suspended in
fixation buffer (BD Biosciences) for 20 min at 4C. Intracellular cytokine and
Foxp3 staining was carried out overnight in permeabilization buffer (BD Biosci-
ences) with PE-, allophycocyanin-, or PE-Cy7-labeled anti-IFN-g, allophyco-
cyanin- or PE-labeled anti-IL-10, and PerCP-Cy5.5-labeled anti-Foxp3 (all
from eBioscience). Cytokine-positive cells were identifed on the basis of an
aliquot of cells from each sample stained with an appropriate isotype control
antibody.
Detection of peptide:I-Ab Complexes and Characterization
of Antigen-Presenting Cells
B6 mice were injected with 25 mg EaRFP+IFA in both ears. At 24 hr or 12 days
after injection, ears and draining lymph nodes were harvested and single-cell
preparations were made, as described above. A separate mouse was injected
with 25 mg OVA+IFA in both ears to serve as a control for background staining.
Cells from each tissue were enriched for Y-Ae+ cells with biotinylated Y-Ae
antibody and magnetic beads (Miltenyi). The enriched cells were stained
with biotinylated Y-Ae antibody (Murphy et al., 1992; Rudensky et al., 1991),
followed by SA-allophycocyanin (eBioscience) and various combinations of
the following antibodies depending on the antigen injected: FITC-labeled
anti-I-A/I-E, Alexa Fluor 750/APC-labeled anti-F4/80, PerCP-Cy5.5-labeled
anti-CD11c, Pacific Blue-labeled anti-CD11b, FITC-labeled anti-B220. All
staining was performed on ice. An LSR II (BD Biosciences) was used for all
flow cytometry, and analysis was performed with FlowJo software (Tree
Star, Ashland, OR).
Sorting and In Vitro Restimulation of TEa T Cells
Single-cell suspensions from the ears or lymph nodes of mice injected with
EaRFP+IFA or OVA+IFA were prepared as described above. Cells were
stained with PE-labeled anti-CD45.2 (clone 104), FITC-labeled anti-CD3, and
allophycocyanin-labeled anti-CD11c. Cells were sorted with a FACSAria
flow cytometer (BD Biosciences). CD3 cells were sorted into the three popu-
lations described in the text. Purified naive TEa cells were labeled with 500 nM
CFSE and mixed 1:1 with the sorted populations in the presence of human
rIL-2 (a generous gift of Matt Mescher) at 0.2 ng/ml. Cells were incubated at
37C/5% CO2 for six days, then stained with Pacific Blue-labeled anti-Va2,
PerCP-labeled anti-CD4, and PE-Cy7-labeled anti-CD90.1. CFSE dilution
was measured in TEa T cells.
Statistics
In Figure 1D and in Figure 1F, a one-way ANOVA or a two-way ANOVA was
used, respectively. For both, a Bonferroni posttest was used for determining
significant differences between groups. For all other data, a two-tailed,
unpaired Student’s t test was used for assessment of the differences between
groups. Prism (Graphpad Software, La Jolla, CA) was used for graphs and
statistical analysis. Differences were considered to be significant when the p
value was less than 0.05. Significant outliers were excluded with the Grubb’s
outlier test (Graphpad Software), shown in Figure 5D.286 Immunity 30, 277–288, February 20, 2009 ª2009 Elsevier Inc.SUPPLEMENTAL DATA
Supplemental Data include three figures and can be found with this article
online at http://www.immunity.com/supplemental/S1074-7613(09)00065-X.
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